MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
2018 ASH Symposium – Presentations Available Below

2016 ASH Symposium - Presentations Available Below

Claim Credits Now

Presentations

Click the links below to view our presentations:

Mutational Impact on Diagnostic and Prognostic Evaluation of MDS
Elsa Bernard, PhD

High-Risk MDS and AML: One or Two Diseases?
Michael Heuser, MD

Myeloid Malignancies Associated with Spliceosome Mutation
Matthew Walter, M.D.

The “AlloHSCT” and prospects for cellular therapy
Ghulam J Mufti

Epigenetic Therapies: What’s next?
Michael Savona, MD

Activity Overview

This symposium will describe recent advances in our understanding of the pathophysiology of myelodysplastic syndromes and related myeloid neoplasms, and how these advances are being translated into more effective treatments for these patients.

Target Audience

This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Describe how to use molecular genetics in diagnostic and prognostic evaluation of MDS.
  • Discuss important factors when comparing High-risk MDS and AML.
  • Recite the pathophysiology of myeloid neoplasms associated with spliceosome mutations.
  • Explain the future of epigenetic therapy.
  • Discuss recent advances in allogeneic transplantation and prospects for cellular therapy.

Featured Faculty

Stephen Nimer, MD – MDSF Chairman

Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida

Mario Cazzola, MD – Symposium Co-Chair

Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy

Moshe Mittelman, MD – Symposium Co-Chair

Director, Department of Medicine
Tel-Aviv Sourasky Medical Center
Tel-Aviv, Israel

Elsa Bernard, PhD

Memorial Sloan Kettering Cancer Center
New York City, New York

Michael Heuser, MD

Heisenberg Chair for Molecular Therapies in Hematology
Hannover Medical School
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover, Germany

Ghulam J. Mufti, DM, FRCP, FRCPath

Head of Department
Professor of Haemato Oncology in Haematological Medicine
King’s College London & King’s College Hospital
London, United Kingdom

Michael Savona, MD

Professor of Medicine
Director of Hematology Research
Director, Hematology Early Therapeutics Program
Vanderbilt-Ingram Cancer Center
Department of Medicine, Division of Hematology & Oncology
Nashville, Tennessee, United States

Matthew Walter, MD

Professor
Washington University School of Medicine in St. Louis
Department of Medicine, Oncology Division
St. Louis, Missouri

Review answers to commonly asked questions or get answers to your questions from an MDS expert